Chemicals and pharmaceutical group Bayer has led a $90m series B round for Germany-based healthcare intelligence technology provider Ada Health through its corporate venture capital subsidiary, Leaps by Bayer.
Consumer electronics manufacturer Samsung also took part in the round, through its Samsung Catalyst Fund, investing together with financial services firm Inteligo Bank, Vitruvian Partners, F4 and Mutschler Ventures.
Ada has created health assessment technology which uses artificial intelligence to help users assess their health through logging their symptoms and then accessing advice on treatment.
Jürgen Eckhardt, head of Leaps by Bayer, said: “Investing in breakthrough technologies that drive digital change in healthcare is one of the strategic imperatives for Leaps by Bayer and for the entire field of healthcare.
“Ada’s truly transformative technology, combining powerful artificial intelligence with an emphasis on medical rigor and high levels of clinical accuracy will lead the way in helping more patients and consumers in achieving better health outcomes sooner by intervening earlier in their healthcare journey.”
The round came after a $46.5m series A in 2017 led by diversified conglomerate Access Industries and backed by June Fund, Cumberland VC and William Tunstall-Pedoe.
